12 results about "Arsenic trioxide" patented technology

The utility model discloses arsenic trioxide grading and bagging equipment which comprises a stock bin and a grading device communicated with the stock bin, the grading device comprises a supporting frame, a device body and a screening assembly, a product discharging port is formed in the bottom of the device body, a long-neck ton bag is arranged below the discharging port, and a fixing plate and a rotating plate are erected below the supporting frame. A bag opening clamping assembly is hinged to the fixing plate, an opening rolling assembly is hinged to the rotating plate, the bag opening clamping assembly comprises a semicircular clamping jaw, a first connecting rod and a first air cylinder connected with the first connecting rod, the semicircular clamping jaw is opposite to the tail end of the discharging opening, and the opening rolling assembly comprises a pressing jaw capable of being buckled, a second connecting rod and a second air cylinder connected with the second connecting rod. And the pressing claw is lower than the discharge hole. Through the arrangement of the grading device, the bag opening clamping assembly and the opening rolling assembly, secondary grading before bagging, automatic bag opening fixing and automatic bag opening tightening after bagging are achieved, manual intervention is little, generation and dissipation of flying dust are effectively avoided, and the automatic bagging machine has the advantages of being controllable in quality and high in operation safety.

The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.

The invention relates to the technical field of medicines, in particular to red date arsenic oxide derived carbon dots as well as a preparation method and application thereof. According to the carbon dots, natural biomass red dates serve as a carbon source, traditional Chinese medicine arsenic oxide serves as an arsenic source, green synthesis is conducted through a hydrothermal method or a pyrolysis method, and subsequent research is conducted on the carbon dots synthesized through the pyrolysis method. Through characterization, the material has a uniform spherical morphology, the particle size is about 1.63 nm, and it is proved that arsenic atoms are successfully doped. The carbon dots have excellent stability in a physiological environment, and have low toxicity and high biocompatibility. In an in-vitro experiment, the apoptosis of the HL-60 acute promyelocytic leukemia can be remarkably induced by inducing ros, promoting differentiation and reducing the protein level of PML-RAR alpha. In in-vivo experiments, APL tumor growth is inhibited, the tumor inhibition rate reaches up to 66.6%, and obvious damage to liver and kidney functions is avoided. The invention overcomes the defects of strong toxicity, inconvenient administration and the like of the existing arsenic trioxide (ATO) for treating APL, provides a novel high-efficiency and low-toxicity therapeutic drug for acute promyelocytic leukemia, and has important clinical transformation value.

The present application relates to a new use of Dihydroquercetin for preventing and treating cardiac toxicity induced by arsenic trioxide, and belongs to the technical field of medicine. In order to solve the problem that the prior art lacks effective treatment means for cardiac toxicity induced by ATO, the present application provides a new use of Dihydroquercetin for preventing and treating cardiac toxicity induced by arsenic trioxide, that is, the application of Dihydroquercetin in the preparation of a medicine for preventing and treating cardiac toxicity induced by arsenic trioxide. The present application proves through experiments that Dihydroquercetin can alleviate cardiac toxicity induced by ATO in multiple ways, including alleviating ATO-induced apoptosis, ferroptosis, oxidative stress, mitochondrial dysfunction and DNA damage. The present application finds that Dihydroquercetin has an excellent effect of preventing and treating cardiac toxicity induced by arsenic trioxide, provides a new strategy for improving the safety of arsenic trioxide, provides an embedding point for preparing a new medicine for preventing and treating cardiac toxicity induced by arsenic trioxide, and has an important clinical application prospect.

The invention provides a pharmaceutical composition for degrading a PML-RAR alpha protein drug-resistant mutant and application of the pharmaceutical composition. The pharmaceutical composition comprises interferon and arsenic trioxide. According to the composition disclosed by the invention, HeLa cells or NB4 cells for expressing the drug-resistant mutant of the PML-RAR alpha fusion protein are jointly treated by using interferon and arsenic trioxide, so that the degradation of the drug-resistant mutant of the PML-RAR alpha fusion protein is specifically induced. The invention provides help for researching the degradation mechanism of the PML-RAR alpha fusion protein drug-resistant mutant and developing drugs for patients with arsenic drug-resistant APL.

The invention provides a preparation method of nanoscale arsenic particles, and belongs to the technical field of nano materials. The invention provides a preparation method of nanoscale arsenic particles, which comprises the following steps: mixing arsenic trioxide and concentrated hydrochloric acid with the mass fraction of 10-35% for double decomposition reaction to obtain a hydrochloric acid aqueous solution of arsenic trichloride; under the oxygen-free condition, arsenic hydride-containing gas is introduced into the hydrochloric acid aqueous solution of arsenic trichloride for a neutralization reaction, the nanoscale arsenic particles are obtained, and the particle size of a single arsenic particle is 65-85 nm. According to the method, safe and practical nanoscale arsenic particles can be obtained by using the arsenic hydride-containing gas and the hydrochloric acid aqueous solution of arsenic trichloride at normal temperature and normal pressure, only water is generated in the neutralization reaction, extra waste residues and waste liquid are not generated, and the method is simple in equipment, less in maintenance, short in process, low in energy consumption and few in by-products.

The invention relates to the technical field of biology, in particular to arsenic trioxide combined copper ions, a carrier and application. Recognition and killing of tumors by inducing tumor cells ICD and activating an autoimmune system are one of effective strategies for solving clinical PD-1 antibody application pain spots at present. The invention clarifies the mechanism and curative effect of inducing tumor cells to generate ICD by combining low-concentration ATO with Cu < 2 + > and sensitizing PD-1 antibody immunotherapy, side effects possibly caused by large-dose application of ATO are avoided to a certain extent, and a new strategy is provided for improving the clinical benefit of the PD-1 antibody and improving the clinical practicability of ATO.

The application discloses an antitumor composition of arsenic trioxide and artesunate for enhancing the drug efficacy of arsenic trioxide, and discloses GA modified pH responsive arsenic trioxide-artesunate double-drug nanoliposome including the composition, the double-drug nanoliposome including glycyrrhetinic acid-polyethylene glycol-hydrazone-distearyphosphatidyl ethanolamine polymer, cholesterol, artesunate and calcium arsenate nanoparticles; the glycyrrhetinic acid-polyethylene glycol-hydrazone-distearyphosphatidyl ethanolamine and cholesterol form nanoliposome, and the nanoliposome is loaded with artesunate and calcium arsenate nanoparticles; the calcium arsenate nanoparticles contain arsenic trioxide, and a preparation method and application in preparing antitumor drugs are disclosed. The application first co-loads the highly toxic traditional Chinese medicine arsenic trioxide and artesunate to play a synergistic effect, realizes the attenuation and efficiency enhancement of arsenic trioxide through targeted modification delivery and tumor microenvironment response release, and has a good clinical application prospect.

The invention discloses an arsenic in-situ growth-metal organic framework material which is arsenic oxide nanoparticles formed in situ on the surface of a metal organic framework material by performing ligand exchange on an arsenic compound and the metal organic framework material, the arsenic compound is selected from sodium arsenite, disodium arsenate heptahydrate, arsenic trioxide and the like; the metal organic framework material is selected from ZIF-8 and the like. The invention also discloses bionic nano-particles for in-situ growth of arsenic. The bionic nano-particles are formed by coating an arsenic in-situ growth-metal organic framework material with a cell membrane. The invention further discloses application of the arsenic in-situ growth-metal organic framework material and the bionic nanoparticles in preparation of drugs for treating cancers. The arsenic in-situ growth-metal organic framework material disclosed by the invention is bionic nano-enzyme with enzyme-like activity and dual epigenetic regulation and control effects, and is uniform in morphology and relatively small in particle size; and due to cell membrane coating, the bone marrow targeting property is realized, the problem of insufficient targeting property of an arsenic compound is solved, and the tumor immunotherapy effect is enhanced.

The invention provides a preparation method of all-transretinoic acid and arsenic trioxide composite nano sustained-release microspheres, which comprises the following steps: a, adding albumin and L-reduced glutathione into deionized water, and carrying out reduction reaction on disulfide bonds in albumin molecules to obtain a reduced albumin aqueous solution; b, taking a sodium hydroxide solution of ATO, and then adding the sodium hydroxide solution of ATO into the reductive albumin aqueous solution obtained in the step a to obtain an ATO-albumin solution; c, ATRA is added into absolute ethyl alcohol and stirred, and an ethyl alcohol solution of ATRA is obtained; d, dropwise adding the ATRA ethanol solution obtained in the step c into the ATO-albumin solution obtained in the step b by using a micro-injection pump to obtain an ATRA and ATO composite nano sustained-release microsphere crude product; and e, centrifuging the crude product, cleaning with deionized water, and freeze-drying to obtain the microsphere product. The preparation method of the product is rapid, simple and convenient, the targeting property is strong, the effect of resisting tumor growth and metastasis of the medicine can be obviously enhanced, and the biological safety is good.

The invention relates to the technical field of biology, in particular to arsenic trioxide combined copper ions, a carrier and application. Recognition and killing of tumors by inducing tumor cells ICD and activating an autoimmune system are one of effective strategies for solving clinical PD-1 antibody application pain spots at present. The invention clarifies the mechanism and curative effect of inducing tumor cells to generate ICD by combining low-concentration ATO with Cu < 2 + > and sensitizing PD-1 antibody immunotherapy, side effects possibly caused by large-dose application of ATO are avoided to a certain extent, and a new strategy is provided for improving the clinical benefit of the PD-1 antibody and improving the clinical practicability of ATO.

The invention provides a method for preparing elemental arsenic by continuous reduction of arsenic trioxide, which comprises the following steps: S1, pelletizing arsenic trioxide powder to obtain a spherical material; s2, heating and distilling the spherical material to generate distilled gas; s3, heating the distillation gas and hydrogen to carry out reduction reaction; s4, pyrolyzing the reduced gas to remove byproducts; and S5, condensing the gas subjected to pyrolysis treatment, and collecting elemental arsenic. According to the method and equipment provided by the invention, the spherical material prepared from the arsenic trioxide powder is heated, distilled, converted into the gaseous state and then reacted with hydrogen, the whole reduction process is a gas-gas reaction, the advantages of active molecular movement and sufficient reaction in the gaseous state are utilized, efficient reduction of arsenic trioxide is realized, the reaction can be continuously carried out, and the production efficiency is improved. And the efficiency is high, the requirement for equipment is low, and arsenic powder output with the ton-level yield can be achieved.